Kiromic BioPharma (NASDAQ:KRBP) versus Lexeo Therapeutics (NASDAQ:LXEO) Financial Contrast

Kiromic BioPharma (NASDAQ:KRBP) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 20.6% of Kiromic BioPharma shares are held by company insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Kiromic BioPharma and Lexeo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	-133.33%
Lexeo Therapeutics	N/A	-155.79%	-51.08%

Analyst Recommendations

This is a summary of recent ratings for Kiromic BioPharma and Lexeo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	N/A
Lexeo Therapeutics	0	0	8	1	3.11

Lexeo Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 72.96%. Given Lexeo Therapeutics’ higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Kiromic BioPharma.

Valuation & Earnings

This table compares Kiromic BioPharma and Lexeo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	-$20.95 million	($9.90)	-0.19
Lexeo Therapeutics	$650,000.00	644.61	-$66.39 million	($22.29)	-0.57

Kiromic BioPharma has higher earnings, but lower revenue than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.

Summary

Lexeo Therapeutics beats Kiromic BioPharma on 6 of the 10 factors compared between the two stocks.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.